Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease

We collected human immunodeficiency virus (HIV) disease progression, surviv al, most recent CD4 cell count, and plasma HIV RNA levels from patients (n = 157) who participated in randomized clinical trials of interleukin (IL)-2 that commenced before 1995. Data were available for 155 (99%) patients. St atistical analyses were based on the intention-to-treat principle. Median f ollow-up was 28 months and 30 months for control and IL-2 patients, respect ively. Twenty-five (16%) patients developed AIDS or died during follow-up ( 16 control patients vs. 9 IL-2 patients; R-2 = 0.57; P = .22). Mean change from baseline CD4 cell count was significantly higher in patients randomize d to receive IL-2 (368 vs. 153 cells/mu L; P = .003). Mean change from base line plasma HIV RNA was significantly lower in patients randomized to recei ve IL-2 (-0.98 vs. -0.63 log copies/mL; P = .004). Significant improvements in CD4 cell count and plasma HIV RNA in recipients of IL-2 relative to con trol patients were associated with a nonsignificant trend toward improved c linical outcome.